Stocktoria
Zai Lab Ltd ZLAB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-28
Zai Lab Ltd statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -49.9% | -70.7% | -137.4% | -188.0% | -485.1% |
| Net margin | -38.1% | -64.4% | -125.5% | -206.1% | -488.2% |
| FCF margin | -34.5% | -55.3% | -77.0% | -182.4% | -393.3% |
| Return on assets | -15.0% | -21.7% | -32.3% | -36.3% | -43.8% |
| Return on equity | -24.5% | -30.6% | -42.0% | -42.4% | -51.1% |
| Current ratio | 2.45 | 3.51 | 4.63 | 8.04 | 7.78 |
| Revenue growth | 15.3% | 49.6% | 24.0% | 49.0% | 194.8% |
Source: SEC EDGAR filings · CIK 0001704292 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.